...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Specific binding of cardiac glycoside drugs and endogenous digitalis-like substances to particulate membrane fractions from human placenta.
【24h】

Specific binding of cardiac glycoside drugs and endogenous digitalis-like substances to particulate membrane fractions from human placenta.

机译:心脏糖苷药物和内源性含量样物质对人胎盘颗粒膜级分的特异性结合。

获取原文

摘要

We studied the characteristics of binding of cardiac glycosides to particulate membrane fractions from human placenta, to demonstrate that placental tissue is a suitable source of receptors for digitalis drugs. Moreover, we performed preliminary experiments with 125I-labeled digoxin and placental particulates to develop a radioreceptor assay for measurement of endogenous substances with activity similar to cardiac glycoside drugs (EDLS). Placental membrane fractions were incubated with [3H]ouabain (10 nmol/L) or 125I-labeled digoxin (50 pmol/L). With both ligands, binding followed a pseudo-first-order reaction kinetics and was saturable. Scatchard analysis revealed a single class of sites [for ouabain, KD = 20.2 +/- 5.8 nmol/L (mean +/- SEM), Bmax = 3.1 +/- 0.9 nmol per gram of protein; for digoxin, KD = 29.7 +/- 1.9 nmol/L, Bmax = 24.3 +/- 1.1 nmol per gram of protein]. As expected, digoxin was less potent than ouabain in displacing both tracers from digitalis drugs receptors; progesterone, cortisone, digitoxose, furosemide, bumetanide, and propranolol had no or little effect. Specific 125I-labeled digoxin binding was competitively inhibited by plasma and (or) urine extracts from newborns, adults, pregnant women, and patients with renal insufficiency. Inhibition of binding and volume of plasma and urine assayed were linearly related. These findings support the hypothesis that cardiac glycosides and EDLS can interact with the human placenta and suggest placental tissue to be a suitable source of receptors for cardiac glycosides.
机译:我们研究了心脏糖苷与人胎盘颗粒膜级分结合的特征,以证明胎盘组织是洋地黄药物的合适受体来源。此外,我们对125i标记的高氧蛋白和胎盘颗粒进行了初步实验,以产生用于测量与心脏糖苷药物(EDL)相似的内源物质的辐射摄取测定。将胎盘膜级分与[3H] Ouabain(10nmol / L)或125i标记的高辛(50pmol / L)一起温育。通过两个配体,结合遵循假一级反应动力学,可饱和。 Scatchard分析揭示了一类网站[瓦巴恩,KD = 20.2 +/- 5.8 nmol / L(平均值+/-扫描型),Bmax = 3.1 +/- 0.9 nmol,每克蛋白质;对于地形辛,KD = 29.7 +/- 1.9 Nmol / L,Bmax = 24.3 +/- 1.1 nmol /克蛋白]。正如预期的那样,Digoxin比Ouabain从洋地黄药物受体中移位的纹遍上的强度较小;黄体酮,可可变酮,位毒素,呋塞米,硼和普萘洛尔没有任何影响。由新生儿,成人,孕妇,肾功能不全的血浆,(或)尿液提取物竞争性地抑制了特异性的125i标记的地形素结合。抑制血浆和尿液的结合和体积测定是线性相关的。这些发现支持心脏糖苷和EDL可以与人胎盘相互作用,并提示胎盘组织是心脏糖苷的合适受体来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号